IL6R and liver cancer: In this set of experiments the three human liver cancer cell lines Hep3B, Huh7 and HepG2 were treated for 24 h with either IL-6 alone (15 ng/mL) or in combination with sIL-6R (100 ng/mL) to simulate classical or IL-6 trans-signaling.